reMYND signs the Statement in support of animal research and a transparent approach

reMYND, has joined with 21 other organisations from across the life sciences sector in signing up to a declaration on openness on animal research.

reMYND to present on Biotechdag

VIB is organising its 5th Biotechday. All ages are welcome to this free event at campus Gasthuisberg in Leuven. reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide. 

IWT supports reMYND in developing a cure for Type 1 Diabetes

reMYND NV today announced that it has received a grant from IWT, the Flemish agency for Innovation by Science and Technology, to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM).

Tulips for Parkinson’s

For 2014, reMYND has dedicated the proceeds of its new year cards to the Vlaamse Parkinson Liga as part of StuBru’s Music-for-Life action.

Ajit Shetty strengthens reMYND’s Board of Directors

reMYND NV today announced that its shareholders have elected Ajit Shetty to join the company’s 4-person Board as an Independent Director.

reMYND receives a positive tax ruling on the income from its Roche collaboration

reMYND NV has received a positive ruling from the Belgian Tax Authorities. The ruling stipulates that the upfront license fee, all milestone payments and royalties linked to Roche Basel will qualify for the patent income deduction under Articles 205 WIB 92.

The strategic alliance between Roche and reMYND is nominated for a Scrip Award

The strategic Alliance between Roche and reMYND to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients is nominated for the Scrip Award “Best Partnership Alliance”. The winners will be announced in London on November 3rd, 2011.

reMYND’s grant from the Michael J Fox Foundation in SciBX

The Science-Business eXchange (SciBX, a publication by the makers of BioCentury and Nature) devoted in its recent publication an article to the role the Michael J Fox Foundation for Parkinson’s Research has been playing in the development of PD therapeutics.

IWT helps to accelerate reMYND’s Diabetes program with a grant of 1.48 million EUR for 2011-2012

reMYND NV today announced that it has received a grant of 1.48 million EUR from IWT, the Flemish agency for Innovation by Science and Technology, to accelerate its Diabetes program.

reMYND’s CRO receives governmental grant for a continued innovation of its offering

On its Board Meeting of April 28th 2011, the governmental Agency for Innovation by Science and Technology (IWT) has approved a grant to reMYND’s Contract Research Organization (CRO) for the ‘Evaluation of candidate behavioral and synaptic markers in tra